High-dose-rate brachytherapy with external beam radiotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer
Abstract To compare the outcomes of localized prostate cancer treatment with high-dose-rate brachytherapy (HDR-BT) and low-dose-rate brachytherapy (LDR-BT), we examined 924 patients treated with HDR-BT + external beam radiotherapy (EBRT) and 500 patients treated with LDR-BT ± EBRT using multi-instit...
Guardado en:
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/2b6a007a3259409b8e17b0cf33beafed |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:2b6a007a3259409b8e17b0cf33beafed |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:2b6a007a3259409b8e17b0cf33beafed2021-12-02T11:39:43ZHigh-dose-rate brachytherapy with external beam radiotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer10.1038/s41598-021-85682-92045-2322https://doaj.org/article/2b6a007a3259409b8e17b0cf33beafed2021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-85682-9https://doaj.org/toc/2045-2322Abstract To compare the outcomes of localized prostate cancer treatment with high-dose-rate brachytherapy (HDR-BT) and low-dose-rate brachytherapy (LDR-BT), we examined 924 patients treated with HDR-BT + external beam radiotherapy (EBRT) and 500 patients treated with LDR-BT ± EBRT using multi-institutional retrospective data. The HDR-BT treated advanced disease with more hormonal therapy than LDR-BT. To reduce background selection bias, we performed inverse probability of treatment weighting (IPTW) analysis using propensity scores and excluded patients with T3b-4 disease/ initial prostate-specific antigen (PSA) levels > 50 ng/ml. The actuarial 5-year biochemical control rates (5y-bNED) were 96.3% and 95.7% in the HDR-BT and LDR-BT groups, respectively. The corresponding values were 100% and 96.5% in the low-risk group; 97.4% and 97.1% in the intermediate-risk group (97.2% and 97% in the higher titer group and 97.5% and 94.6% in the lower titer group, respectively); and 95.7% and 94.9% in the selected high-risk group, respectively. IPTW correction indicated no significant difference among the groups. The 5y-bNED in the HDR-BT + EBRT, LDR-BT + EBRT, and LDR-BT alone groups were 96.3%, 95.5%, and 97%, respectively (P = 0.3011). The corresponding values were 97.4%, 94.7%, and 96.6% (P = 0.1004) in the intermediate-risk group (97.5%, 100%, and 94.5% in the lower titer group [P = 0.122] and 97.2%, 96.2%, and 100% [P = 0.664] in the higher titer group, respectively) and 95.7%, 95.5%, and 100% (P = 0.859) in the high-risk group, respectively. The HDR-BT group showed a lower incidence of acute grade ≥ 2 genitourinary toxicities; the incidence of other early and late grade ≥ 2 toxicities were similar between the HDR-BT and LDR-BT groups. Acute genitourinary toxicity predicted the occurrence of late genitourinary toxicity. EBRT increased the risk of grade ≥ 2 gastrointestinal toxicity. HDR-BT + EBRT is a good alternative to LDR-BT ± EBRT for low-, intermediate-, and selected high-risk patients.Hideya YamazakiKoji MasuiGen SuzukiNorihiro AibeDaisuke ShimizuTakuya KimotoKei YamadaAkihisa UenoToru MatsugasumiYasuhiro YamadaTakumi ShiraishiAtsuko FujiharaKoji OkiharaKen YoshidaSatoaki NakamuraNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Medicine R Science Q |
spellingShingle |
Medicine R Science Q Hideya Yamazaki Koji Masui Gen Suzuki Norihiro Aibe Daisuke Shimizu Takuya Kimoto Kei Yamada Akihisa Ueno Toru Matsugasumi Yasuhiro Yamada Takumi Shiraishi Atsuko Fujihara Koji Okihara Ken Yoshida Satoaki Nakamura High-dose-rate brachytherapy with external beam radiotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer |
description |
Abstract To compare the outcomes of localized prostate cancer treatment with high-dose-rate brachytherapy (HDR-BT) and low-dose-rate brachytherapy (LDR-BT), we examined 924 patients treated with HDR-BT + external beam radiotherapy (EBRT) and 500 patients treated with LDR-BT ± EBRT using multi-institutional retrospective data. The HDR-BT treated advanced disease with more hormonal therapy than LDR-BT. To reduce background selection bias, we performed inverse probability of treatment weighting (IPTW) analysis using propensity scores and excluded patients with T3b-4 disease/ initial prostate-specific antigen (PSA) levels > 50 ng/ml. The actuarial 5-year biochemical control rates (5y-bNED) were 96.3% and 95.7% in the HDR-BT and LDR-BT groups, respectively. The corresponding values were 100% and 96.5% in the low-risk group; 97.4% and 97.1% in the intermediate-risk group (97.2% and 97% in the higher titer group and 97.5% and 94.6% in the lower titer group, respectively); and 95.7% and 94.9% in the selected high-risk group, respectively. IPTW correction indicated no significant difference among the groups. The 5y-bNED in the HDR-BT + EBRT, LDR-BT + EBRT, and LDR-BT alone groups were 96.3%, 95.5%, and 97%, respectively (P = 0.3011). The corresponding values were 97.4%, 94.7%, and 96.6% (P = 0.1004) in the intermediate-risk group (97.5%, 100%, and 94.5% in the lower titer group [P = 0.122] and 97.2%, 96.2%, and 100% [P = 0.664] in the higher titer group, respectively) and 95.7%, 95.5%, and 100% (P = 0.859) in the high-risk group, respectively. The HDR-BT group showed a lower incidence of acute grade ≥ 2 genitourinary toxicities; the incidence of other early and late grade ≥ 2 toxicities were similar between the HDR-BT and LDR-BT groups. Acute genitourinary toxicity predicted the occurrence of late genitourinary toxicity. EBRT increased the risk of grade ≥ 2 gastrointestinal toxicity. HDR-BT + EBRT is a good alternative to LDR-BT ± EBRT for low-, intermediate-, and selected high-risk patients. |
format |
article |
author |
Hideya Yamazaki Koji Masui Gen Suzuki Norihiro Aibe Daisuke Shimizu Takuya Kimoto Kei Yamada Akihisa Ueno Toru Matsugasumi Yasuhiro Yamada Takumi Shiraishi Atsuko Fujihara Koji Okihara Ken Yoshida Satoaki Nakamura |
author_facet |
Hideya Yamazaki Koji Masui Gen Suzuki Norihiro Aibe Daisuke Shimizu Takuya Kimoto Kei Yamada Akihisa Ueno Toru Matsugasumi Yasuhiro Yamada Takumi Shiraishi Atsuko Fujihara Koji Okihara Ken Yoshida Satoaki Nakamura |
author_sort |
Hideya Yamazaki |
title |
High-dose-rate brachytherapy with external beam radiotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer |
title_short |
High-dose-rate brachytherapy with external beam radiotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer |
title_full |
High-dose-rate brachytherapy with external beam radiotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer |
title_fullStr |
High-dose-rate brachytherapy with external beam radiotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer |
title_full_unstemmed |
High-dose-rate brachytherapy with external beam radiotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer |
title_sort |
high-dose-rate brachytherapy with external beam radiotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer |
publisher |
Nature Portfolio |
publishDate |
2021 |
url |
https://doaj.org/article/2b6a007a3259409b8e17b0cf33beafed |
work_keys_str_mv |
AT hideyayamazaki highdoseratebrachytherapywithexternalbeamradiotherapyversuslowdoseratebrachytherapywithorwithoutexternalbeamradiotherapyforclinicallylocalizedprostatecancer AT kojimasui highdoseratebrachytherapywithexternalbeamradiotherapyversuslowdoseratebrachytherapywithorwithoutexternalbeamradiotherapyforclinicallylocalizedprostatecancer AT gensuzuki highdoseratebrachytherapywithexternalbeamradiotherapyversuslowdoseratebrachytherapywithorwithoutexternalbeamradiotherapyforclinicallylocalizedprostatecancer AT norihiroaibe highdoseratebrachytherapywithexternalbeamradiotherapyversuslowdoseratebrachytherapywithorwithoutexternalbeamradiotherapyforclinicallylocalizedprostatecancer AT daisukeshimizu highdoseratebrachytherapywithexternalbeamradiotherapyversuslowdoseratebrachytherapywithorwithoutexternalbeamradiotherapyforclinicallylocalizedprostatecancer AT takuyakimoto highdoseratebrachytherapywithexternalbeamradiotherapyversuslowdoseratebrachytherapywithorwithoutexternalbeamradiotherapyforclinicallylocalizedprostatecancer AT keiyamada highdoseratebrachytherapywithexternalbeamradiotherapyversuslowdoseratebrachytherapywithorwithoutexternalbeamradiotherapyforclinicallylocalizedprostatecancer AT akihisaueno highdoseratebrachytherapywithexternalbeamradiotherapyversuslowdoseratebrachytherapywithorwithoutexternalbeamradiotherapyforclinicallylocalizedprostatecancer AT torumatsugasumi highdoseratebrachytherapywithexternalbeamradiotherapyversuslowdoseratebrachytherapywithorwithoutexternalbeamradiotherapyforclinicallylocalizedprostatecancer AT yasuhiroyamada highdoseratebrachytherapywithexternalbeamradiotherapyversuslowdoseratebrachytherapywithorwithoutexternalbeamradiotherapyforclinicallylocalizedprostatecancer AT takumishiraishi highdoseratebrachytherapywithexternalbeamradiotherapyversuslowdoseratebrachytherapywithorwithoutexternalbeamradiotherapyforclinicallylocalizedprostatecancer AT atsukofujihara highdoseratebrachytherapywithexternalbeamradiotherapyversuslowdoseratebrachytherapywithorwithoutexternalbeamradiotherapyforclinicallylocalizedprostatecancer AT kojiokihara highdoseratebrachytherapywithexternalbeamradiotherapyversuslowdoseratebrachytherapywithorwithoutexternalbeamradiotherapyforclinicallylocalizedprostatecancer AT kenyoshida highdoseratebrachytherapywithexternalbeamradiotherapyversuslowdoseratebrachytherapywithorwithoutexternalbeamradiotherapyforclinicallylocalizedprostatecancer AT satoakinakamura highdoseratebrachytherapywithexternalbeamradiotherapyversuslowdoseratebrachytherapywithorwithoutexternalbeamradiotherapyforclinicallylocalizedprostatecancer |
_version_ |
1718395692427247616 |